Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly

April 18, 2017 updated by: Roberta Oka, Palo Alto Veterans Institute for Research
The proposed preliminary study from this interdisciplinary team will provide important information about the feasibility and safety of bedside low intensity pedaling exercise during hospitalization. The findings from this study are essential to develop high-value, effective treatments that can be used by any hospital setting throughout the country. The program that investigators are proposing may provide important changes in how disability can be prevented in elderly patients who are hospitalized because of an acute illness.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The study design includes 2 phases (10 months each) for development and evaluation of the testing and intervention protocol. The last 4 months of the study will be devoted to preparation of a larger randomized controlled clinical trial grant submission. Mixed methods will be used in both phases.

Phase I will focus on developing, testing and refining the measurement protocol and bedside tailored low intensity pedaling exercise (Ex) program using mixed methods. During this 10-month phase, researchers plan to enroll 10 participants who are admitted to a medical surgical (MS) unit and meet study eligibility criteria. Investigators will implement our proposed testing and intervention protocol,obtain feedback and make modifications as necessary. For this purpose the study team will use a process improvement framework with rapid cycle improvements. The outcome for Phase I will be development of a manual of operations for the testing and Ex protocol that will be implemented in Phase II.

Phase II (10 months) will randomly assign 60 patients over the age of 65 years who meet medical criteria and are admitted to a medical surgical (MS) hospital unit at the VA Palo Alto Health care system (VAPA HCS) to one of two groups, 1) low intensity bedside pedaling exercise or 2) usual care. All participants will be asked to complete questionnaires, undergo a Short Physical Performance Battery (SPPB), cognitive testing and a blood draw prior to participation in the Ex program (baseline). All testing and blood draw will be repeated within 24 hours prior to discharge (release from the hospital to home or other facility, indicating that their condition has been resolved or adequately treated or is stabilized during their hospital stay) from the hospital(approximately at 5-6 days). Participants will be followed for the duration of the hospital stay, an expected average length of 5-6 days. Additionally, all participants will be asked to continue to exercise after discharge to home for 4 weeks. All tests will be performed at baseline (prior to intervention), within 24 hours prior to discharge (release from the hospital to home or other facility, indicating that their condition has been resolved or adequately treated or is stabilized during their hospital stay)from the hospital, on average 5-6 days) and again at 4 weeks post discharge. The focus of Phase II is safety and feasibility of the intervention and association with outcome measures. The length of stay (LOS) at VAPA HCS is approximately 6 days. Thus, the study investigators anticipate that each individual will be enrolled approximately 5 days and participate in an average of 8 training sessions. Investigators will also examine the association between physical activity levels at baseline (pre Ex) and myokines and associated changes in myokines after intervention.

A description of the Ex program:

Individually tailored, low intensity bedside pedaling exercise:

Once participants complete the testing protocol they will be instructed in the bedside Ex program. Exercise intensity and duration will be individualized to the subject's physical limitations and tolerance. The PI is an Adult Nurse Practitioner (ANP), and will supervise and monitor exercise response including Heart Rate (HR), Blood Pressure (BP), Rating of Perceived Exertion (RPE), and symptoms (intensity, duration). Exercise will be terminated according to the American College of Sports Medicine (ACSM) criteria. Ex will consist of progressively increased pedaling exercise performed initially for one-two minutes, three times or more daily as tolerated. Pedaling exercise will be progressively increased as tolerated and appropriate. Cycle ergometry has been shown to be an effective exercise modality to maintain muscle strength and aerobic capacity in a variety of age groups. While inpatient exercise prescriptions utilize walking as the primary mode of exercise, recent studies show that despite known benefits of ambulation, multiple barriers prevent routine implementation in practice settings. The study investigators propose to examine the feasibility of a portable bedside pedaling device for exercise. This modality eliminates dependence on hospital staff to supervise ambulation and allows patients greater access to optimal treatment recommendations to maintain functional independence. This exercise modality is not new, but bedside use is novel. The pedaling device is sturdy and portable and will be placed at the foot of an anchored chair. Subjects will be able to pedal without fear of falling or interference from other devices. This exercise will be performed in addition to their normal ambulation requirements. All catheters and other devices will be secured so that accidental removal will not occur during the Ex session.

Adherence is a key component of this study and will be monitored during both phases of the pilot study. Adherence will be assessed by direct observation from PI/staff. Investigators will also examine potential barriers and facilitators to exercise training adherence by obtaining qualitative feedback from study participants. The qualitative information will provide greater depth of understanding to improve the delivery of the intervention as well as assist in optimizing adherence.

The Study team will also ask participants if they are willing to be contacted regarding future research that may be of interest to them.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Palo Alto, California, United States, 94304
        • VA Palo Alto HCS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • English speaking
  • age 65 years or older
  • Able to tolerate exercise
  • Non-elective admission to hospital

Exclusion Criteria:

  • Elective admission with expected LOS of 2 days or less
  • Diagnosed with Dementia or Alzheimer's disease
  • Lower extremity amputation
  • Delirium
  • Severe arthritis limiting ability to perform pedaling exercise
  • Uncontrolled hypertension
  • Hypotension
  • Non-English speaking
  • Participating in another clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: exercise
daily bedside tailored low intensity pedaling exercise
daily tailored low level pedaling exercise at bedside

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activities of Daily Living
Time Frame: Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)
Discharge is considered release from the hospital to home or other facility, indicating that their condition has been resolved or adequately treated or is stabilized during their hospital stay. On average we anticipate the time frame between hospital admission and discharge to be variable but between 3-5 days in length.
Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Instrumental Activities of Daily Living
Time Frame: Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)
Discharge is release from the hospital to home or other facility, indicating that their condition has been resolved or adequately treated or is stabilized during their hospital stay. On average we anticipate the time frame between hospital admission and discharge to be variable but between 3-5 days in length.
Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)
Short Physical Performance Battery
Time Frame: Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)
Discharge is release from the hospital to home or other facility, indicating that their condition has been resolved or adequately treated or is stabilized during their hospital stay. On average we anticipate the time frame between hospital admission and discharge to be variable but between 3-5 days in length.
Change from Baseline (Admission) to Discharge (approximately 3-5 days in length)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roberta K Oka, PhD, RN, VA Palo Alto HCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Actual)

August 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

June 21, 2013

First Submitted That Met QC Criteria

July 16, 2013

First Posted (Estimate)

July 17, 2013

Study Record Updates

Last Update Posted (Actual)

April 20, 2017

Last Update Submitted That Met QC Criteria

April 18, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • OKR0003ADM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on exercise

Subscribe